Factors associated with positive tuberculin skin test results among HIV-infected persons in Orel Oblast, Russia

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 7, 2009, Pages 829-835

  Vitek, Erika ^a,b,e   Gusseinova, N ^b,c   Laricheva, N ^c   Vasiliev, S ^c   Molotilov, V ^c   Sofronova, R ^c   Kazionny, B ^c   Cegielski, P ^a   Nguyen, M L ^d   Nelson, L ^a   Agerton, T ^a   Wells, C ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b US Civilian Research Development Foundation   (Russian Federation)

^c TB Dispensary and Ministry of Health   (Russian Federation)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

HIV; Latent tuberculosis infection; Tuberculin skin test

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION RISK; LATENT PERIOD; MALE; PREVALENCE; PRIORITY JOURNAL; RUSSIAN FEDERATION; TUBERCULIN TEST; TUBERCULOSIS;

EID: 67651216267     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
2. World Health Organization. WHO guidelines for implementing collaborative TB and HIV programme activities 2003. WHO/CDS/TB/2003.319. WHO/HIV/2003.01. Geneva, Switzerland: WHO, 2003.
3. Hawken M P, Meme H K, Elliott L C, et al. Isoniazid preventive therapy for tuberculosis in HIV-1 infected adults: results of a randomized controlled trial. AIDS 1997; 11: 875-882. (Pubitemid 27226410)
4. World Health Organization/Joint United Nations Program on HIV/AIDS. Preventive therapy against tuberculosis in people living with HIV - policy statement. Wkly Epidemiol Record 1999; 74: 385-398.
5. World Health Organization. WHO report 2006. Global tuberculosis control. WHO/HTM/TB/2006.362. Geneva, Switzerland: WHO, 2006.
6. Kherosheva T, Thorpe L E, Kiryanova E, et al. Encouraging outcomes in the first year of a TB control demonstration program: Orel Oblast, Russia. Int J Tuberc Lung Dis 2003; 7: 1045-1051. (Pubitemid 37376954)
7. Molotilov V, Sofronova R, Gusseynova N, et al. Rapid increase in HIV rates - Orel oblast, Russian Federation, 1999-2001. MMWR 2003; 52: 657-660.
8. Pokrovski W, Ladnaya N N, Buratzova E V. HIV infection - Bulletin. Moscow, Russian Federation: Russian Federal Center for Prevention of AIDS, 2002.
9. Joint United Nations Program on HIV/AIDS. 2006 report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS, 2006.
10. Kazionny B, Wells C D, Kluge H, Gusseynova N, Molotilov V. Implications of the growing HIV-1 epidemic for tuberculosis control in Russia. Lancet 2001; 358: 1513-1514. (Pubitemid 33055706)
11. World Health Organization. 2007 annual TB report. Country profile: Russian Federation. WHO/HTM/TB/2007.376. Geneva, Switzerland: WHO, 2007.
12. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021. (Pubitemid 36548927)
13. Drobniewski F, Balabanova Y, Zakamova E, Nikolayevskyy V, Fedorin I. Rates of latent tuberculosis in health care staff in Russia. PLoS Med 2007; 4: e55. (Pubitemid 46354440)
14. Rangaka M X, Wilkinson K A, Seldon R, et al. Effect of HIV-1 infection on T cell based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: 514-520. (Pubitemid 46354256)
15. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102. (Pubitemid 44968992)
16. Tegbaru B, Wolday D, Messele T, et al. Tuberculin skin test conversion and reactivity rates among adults with and without human immunodeficiency virus in urban settings in Ethiopia. Clin Vaccine Immunol 2006; 13: 784-789.
17. Portu J J, Aldamiz-Etxebarria M, Agud J M, Arevalo J M, Almaraz M J, Ayensa C. Tuberculin skin testing in intravenous drug users: differences between HIV seropositive and HIV seronegative subjects. Addiction Biol 2002; 7: 235-241.
18. Garcia-Garcia M de L, Valdespino-Gomez J L, Garcia-Sancho C, et al. Underestimation of Mycobacterium tuberculosis infection in HIV infected subjects using reactivity to tuberculin and anergy panel. Int J Epidemiol 2000; 29: 369-375. (Pubitemid 30209832)
19. Graham N M, Nelson K, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV 1-seropositive and seronegative intravenous drug users. JAMA 1992; 267: 369-373.
20. Markowitz N, Hansen N I, Wilcosky T C, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119: 185-193. (Pubitemid 23327617)
21. United Nations General Assembly Special Session (UNGASS). 2008 UNGASS Report, Russian Federation. New York, NY, USA: UN, 2008. http://data.unaids.org/ pub/Report/2008/russia-2008-country-progress-report-ru.pdf Accessed July 2008.
22. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev 1: CD000171.
23. Fernandez-Villar A, Sopena B, Vazquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003; 36: 293-298. (Pubitemid 36169664)
24. World Health Organization. World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance 2002-2007. WHO/HTM/TB/2008.39. Geneva, Switzerland: WHO, 2008.